课题基金 / 基金详情

Project 1: Systematic discovery of cell-intrinsic mechanisms of cancer drug resistance

Project 1: Systematic discovery of cell-intrinsic mechanisms of cancer drug resistance
项目1:系统发现癌症耐药的细胞内在机制
批准号:
10162308
负责人:
SCOTT R MANALIS
金额:
$65.24万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-06-07 至 2023-04-30

项目摘要

项目成果

SCOTT R MANALIS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project 1 – Project Summary Despite tremendous advances in our understanding of cancer pathogenesis, the treatment of individual patients with either conventional chemotherapy or targeted agents remains highly empiric. To date, precision medicine efforts in oncology have focused primarily on genetic or epigenetic biomarkers within an individual tumor. However, not all marker-based predictions guarantee patient response, as many are the result of correlations from population-based studies. Approaches that utilize individual patient tumors specimens for ex vivo drug susceptibility testing are similarly limited by the process of generating a cell line and subsequent effects on drug sensitivity. Existing assays that measure cancer cell growth, such as ATP-based growth assays (CellTiter-Glo), require extended culture and a large volume of tumor cells. This precludes their use for disease monitoring in most patients with cancer. Furthermore, these bulk approaches are ill-suited for characterizing therapeutic susceptibility within subpopulations. Thus, there is a pressing need for rapid and facile approaches to characterize therapeutic sensitivity within individual tumor specimens that capture heterogeneity and can be applied to very small specimens, including minimal residual disease. Project 1 leverages a unique suite of tools to profile the intrinsic factors that inform the responses of individual cancer cells to therapeutic interventions. We will ask to what extent paired phenotypic and transcriptomic measurements can identify pathways that mediate cell autonomous resistance and highlight therapeutic approaches to overcome that resistance. Cancer cells will be isolated from primary tumors or from patient-derived cell lines/xenografts of both leukemias (as a liquid tumor model) and colon/pancreatic cancers (as a solid tumor model). In contrast to Project 2, cells will be measured in isolation without mimicking aspects of the microenvironment. Over a period of many hours, we will examine distinct phenotypic attributes of the cells (mass and mass accumulation rate) and link these attributes to the transcriptome at the single-cell level. We will then determine cell intrinsic mechanisms for resistance by analyzing transcriptomic features of responding and non-responding tumor cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Measuring single-cell water content non invasively and with high precision
Building microenvironment-containing organoids from patient samples with single-cell precision
Administrative Core
Single cell growth assay for residual cells in acute lymphoblastic leukemia
海外基金